Rhythm re­ceives ex­pand­ed ap­proval for ge­net­ic obe­si­ty drug

Rhythm Phar­ma­ceu­ti­cals re­ceived FDA ap­proval to mar­ket its ge­net­ic obe­si­ty drug Im­civree for chil­dren as young as 2 years old.

Fri­day’s ac­tion will let the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER